Alvotech (ALVO) Form 6-K — Oct 14, 2026
Alvotech and Advanz Pharma announced the first known regulatory submission worldwide for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), filed with the European Medicines Agency on October 14, 2026. The application was submitted as a line extension to the existing European marketing authorization for Mynzepli, Alvotech's approved biosimilar to Eylea 2 mg. The 8 mg formulation permits 16-week treatment intervals for certain patients versus the standard 8-week interval. The high-dose segment is growing fast: Eylea 8 mg accounted for roughly 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, up from about 30% a year earlier.
Key figures
- Eylea 8mg treatment interval
- 16 weeks vs 8 weeks standard
- Alvotech approved biosimilars marketed
- 5
- Eylea 8mg share of combined sales q2 2025
- ~30%
- Eylea 8mg share of combined sales q2 2026
- ~57%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.